GS-9160
GS-9160 is a HIV-1 integrase strand transfer inhibitor with an IC50 of 28 nM. GS-9160 elevates the level of HIV-1 double long terminal repeat circles and reduces integration junctions. GS-9160 exhibits selective antiviral activity against HIV-1 in cells. GS-9160 can select for integrase mutants E92V and L74M, and shows synergistic activity with other HIV-1 inhibitors. GS-9160 can be used in studies related to HIV-1 infection.
For research use only. We do not sell to patients.
- CAS No.: 915407-80-6
- Formula: C20H18FN3O4S
- Molecular Weight:415.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
GS-9160 (range; 30 min) potently inhibits purified HIV-1 integrase strand transfer activity with an IC50 of 28 nM[1].
GS-9160 (5 days) potently inhibits HIV-1 IIIb replication in MT-2 cells with an EC50 of 2.1 nM and a selectivity index of 1,905[1].
GS-9160 (5 days) potently inhibits HIV-1 IIIb replication in MT-4 cells with an EC50 of 0.7 nM and a selectivity index of 457[1].
GS-9160 (5 days) potently inhibits HIV-1 BaL replication in primary human CD4-positive T lymphocytes with an EC50 of 1.5 nM and a selectivity index of 2,667[1].
GS-9160 (tested doses; period sufficient for viral replication and circle formation) blocks HIV-1 integration in SupT1 cells, as evidenced by a 1.9-fold increase in 2-LTR circle levels, with a cytotoxicity CC50 of 600 nM[1].
GS-9160 (48 h) specifically inhibits HIV-1 integration in SupT1 cells, reducing integration junctions with an EC50 of 0.9 nM without affecting late reverse transcription product accumulation[1].
GS-9160 potently inhibits HIV replication in vitro, though its activity is reduced in human serum, and it selects for HIV-1 integrase mutations integraseE92V and integraseL74M that are shared with other integrase strand transfer inhibitors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MT-2 T-lymphoblastoid cells
-
Concentration:serially diluted (nine concentrations)
-
Incubation Time:5 days
-
Result:Exhibited potent anti-HIV-1 activity with a mean EC50 of 2.1 nM and a selectivity index (CC50/EC50) of 1,905, with a mean CC50 of 4,000 nM.
-
Cell Line:MT-4 T-lymphoblastoid cells
-
Concentration:serially diluted (nine concentrations)
-
Incubation Time:5 days
-
Result:Potently inhibited HIV-1 IIIb replication with a mean EC50 of 0.7 nM and a selectivity index of 457, with a mean CC50 of 320 nM.
-
Cell Line:MT-2 cells, primary human CD4-positive T lymphocytes
-
Concentration:serially diluted; serum conditions included 10%, 20%, 35%, 50% human serum, or HSA + α1-AGP
-
Incubation Time:5 days
-
Result:Increased the EC50 7.1-fold to 15 nM in MT-2 cells treated with HSA and α1-AGP, while 100% extrapolated human serum increased the EC50 6-fold to 12 nM.
Increased the EC50 10-fold to 15 nM in primary human T cells treated with HSA + α1-AGP.
-
Cell Line:SupT1 cells
-
Concentration:tested doses
-
Incubation Time:period sufficient for viral replication and circle formation
-
Result:Resulted in an approximate 1.9-fold increase in 2-LTR circle levels, indicating blocked HIV-1 integration, with a mean CC50 of 600 nM.
-
Cell Line:MT-2 cells
-
Concentration:serially diluted combination concentrations
-
Incubation Time:5 days
-
Result:Showed highly synergistic activity with all tested antiretrovirals, with MacSynergy II volumes ranging from 153.7 to 410.5 nM2·% and CI values ranging from 0.373 to 0.751, consistent with synergism or moderate synergism.
Chemical Information
-
CAS No. 915407-80-6
-
Molecular Weight 415.44
-
Formula C20H18FN3O4S
-
SMILES
O=C1C=2C(O)=C3N=CC=CC3=C(C2CN1CC4=CC=C(F)C=C4)N(C)S(=O)(=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Jones GS, et al. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrobial agents and chemotherapy. 2009 Mar;53(3):1194-203. [Content Brief]
[2]. Choi E, et al. Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase. Future Sci OA. 2018 Sep 6;4(9):FSO338. [Content Brief]
[3]. Alian A, et al. Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proceedings of the National Academy of Sciences of the United States of America. 2009 May 19;106(20):8192-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GS-9160 Related Classifications
HY-184318 Related Classifications
Powered by Bioz
- GS-9160
- 915407-80-6
- GS9160
- GS 9160
- HIV Integrase
- HIV
- primary human CD4-positive T lymphocytes
- HIV-1 integrase mutations
- MT-2 cells
- nonnucleoside reverse transcriptase inhibitors
- MT-4 cells
- primary human T lymphocytes
- HIV-1 protease inhibitors
- SupT1 cells
- HIV-1 integrase
- nucleoside/nucleotide reverse transcriptase inhibitors
- Inhibitor
- inhibitor
- inhibit